Israeli Scientists Develop Blood Test That Detects Breast Cancer With 95% Accuracy
Weizmann Institute and Hebrew University researchers created a blood test that detects early breast cancer and predicts recurrence risk using epigenetic markers.
Researchers at the Weizmann Institute of Science and the Hebrew University of Jerusalem have developed a blood test that can distinguish early-stage breast cancer from healthy tissue with 95 percent accuracy, according to a study published in Nature. The work, led by Prof. Efrat Shema of Weizmann and Prof. Guy Ron of Hebrew University, grew out of a collaboration with physicians at Kaplan Medical Center in Rehovot, Sheba Medical Center and the Mayo Clinic in Florida. The test, a form of liquid biopsy, also outperformed conventional tissue biopsies in predicting whether cancer would return after treatment.
The team, including Dr. Noa Furth and Dr. Christina Riemenschneider of Shema's lab, first mapped the epigenetic tags that control gene activity in tumor tissue removed from 12 women during surgery. These chemical markers do not change the DNA sequence itself but influence which genes a cell uses. Using single-molecule microscopy developed in Shema's lab, the scientists then searched for matching epigenetic patterns on nucleosomes, fragments of DNA released into the bloodstream when cells die, including cancer cells. Ron's physics group analyzed the resulting data with computational models and trained artificial intelligence to recognize patterns associated with disease.
Tested on blood samples from 77 breast cancer patients followed for at least five years at the Mayo Clinic and 30 healthy women, the test identified early tumors measuring no more than two centimeters with 95 percent accuracy, regardless of breast density, a factor that can obscure tumors on mammograms. The researchers also found that even tumors not considered aggressive can harbor a small population of highly invasive cells with a distinct epigenetic signature. Tracking this signature in blood samples let the team predict, with 81 percent accuracy, which patients would experience a recurrence, including some classified as low risk by standard measures.
"Breast cancer screening saves lives," Shema said, noting that the new blood test performed consistently across breast cancer types and density levels. The team now plans to expand testing and search for treatments that could prevent cancer cells from becoming more aggressive by altering their epigenetic flexibility.
“Breast cancer screening saves lives”
The blood test could give doctors an earlier, less invasive way to detect breast cancer and identify patients at high risk of recurrence, regardless of breast density. By flagging aggressive cell populations missed by standard risk assessments, it may help doctors tailor follow-up care and catch relapses sooner.
Sources
- Cancer Leaves Its Mark: New Blood Test Detects Early Breast Cancer and Helps Predict Its ReturnWeizmann Institute of Science, November 11, 2026
- Epigenetic heterogeneity in breast tumours informs diagnosis and prognosis | Naturenature.com, November 11, 2026
Summarised in our own words from the reporting above.
Tikkun olam, today. This is part of tikkun olam, the Jewish idea of repairing the world, and every one of us can add to it.